We are releasing on Monday morning to maximize the exposure of the release in the US markets. There is great expectation for this announcement and a Monday morning release will ensure we reach the widest audience possible. My explanation to your Board would focus on that fact that this timing of this important announcement by Neurelis cannot be pre-empted by another announcement of the approval. This would create confusion and the appropriate resources to support the announcement (updates to Neurelis website, the official www.valtoco.com website launch) will not become active until Monday morning. We have to ensure that all of our Valtoco materials and documentations are consistent with the FDA approved labeling provided in the Approval letter. This will be completed by the time of the release.